(Q37083130)

English

A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome

scientific article published on February 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

0 references

author name string

Clete A Kushida

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Arthur S Walters

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Philip Becker

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Stephen G Thein

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

A Thomas Perkins

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Thomas Roth

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Daniel Canafax

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Ronald W Barrett

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

XP021 Study Group

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 February 2009

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

32

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

159-168

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

29 September 2017

Restless legs syndrome prevalence and impact: REST general population study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

29 September 2017

Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

29 September 2017

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

29 September 2017

Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

29 September 2017

Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

29 September 2017

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

29 September 2017

Gabapentin versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

29 September 2017

Treatment of idiopathic restless legs syndrome (RLS) with gabapentin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

29 September 2017

Gabapentin in the management of convulsive disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

29 September 2017

Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

29 September 2017

Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

27 June 2018

Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

27 June 2018

Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

27 June 2018

Efficacy and safety of pramipexole in restless legs syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Restless legs syndrome: a community-based study of prevalence, severity, and risk factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Long-term treatment of restless legs syndrome with dopamine agonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Evaluating the quality of life of patients with restless legs syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Ropinirole for restless legs syndrome: a placebo-controlled crossover trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Restless legs syndrome symptoms in primary care: a prevalence study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Gabapentin increases slow-wave sleep in normal adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635579

3 September 2018

Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19238802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful treatment of reflex sympathetic dystrophy with gabapentin

1 reference

https://pubmed.ncbi.nlm.nih.gov/19238802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of restless legs syndrome with gabapentin (Neurontin)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19238802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of restless legs syndrome with gabapentin

1 reference

https://pubmed.ncbi.nlm.nih.gov/19238802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability

1 reference

https://pubmed.ncbi.nlm.nih.gov/19238802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/SLEEP/32.2.159

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37083130&oldid=2105425013"